SM-130686, a novel oxindole-based oral GH secretagogue structurally distinct from MK-677 and GHRP, showed potent GH-releasing activity in vitro and in vivo with body weight and IGF-1 increases in rats.
New chemical classSM-130686's oxindole structure is completely different from MK-677, GHRP, or NN703 — yet it potently activates the same receptor
What the researchers found
SM-130686, a structurally novel oxindole GH secretagogue, showed potent in-vitro and in-vivo GH-releasing activity, increased IGF-1 and body weight in rats, and was orally active, demonstrating a new chemical class for GHS-R targeting.
Why it matters
Having structurally diverse drugs for the same target provides backup options if one class has safety issues, and may reveal compounds with better selectivity or pharmacokinetics.
How the study worked
Preclinical pharmacology study. SM-130686 tested in rat pituitary cell assays (in vitro), acute GH release in rats and dogs (in vivo), and chronic dosing for body weight and IGF-1 effects.
What this study cannot tell us
Preclinical data only. Selectivity profile not fully characterized. Long-term safety unknown. No human data.
How to read the evidence
Preliminary preclinical evidence with comprehensive in-vitro and in-vivo pharmacology demonstrating a new viable GH secretagogue chemical class.
When this study was published
Published in 2001. SM-130686 represented one of several novel chemical approaches being explored for GH secretagogue drug development.
The bigger picture
Drug development benefits from chemical diversity. Multiple structural classes targeting the same receptor provide safety alternatives and opportunities for discovering compounds with superior drug properties.
Questions still open
- Does the novel scaffold provide advantages over MK-677?
- What is SM-130686's selectivity profile?
- Will it advance to human clinical trials?
Common questions
Why develop a different type of GH secretagogue?
How does this compare to MK-677?
Read the original research
Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.
The Journal of endocrinology, 171(3), 481-9
Citation
Nagamine, J; Nagata, R; Seki, H; Nomura-Akimaru, N; Ueki, Y; Kumagai, K; Taiji, M; Noguchi, H. (2001). Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.. The Journal of endocrinology, 171(3), 481-9.